Shouxi Xu
About
Shouxi Xu is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Immunology.
According to data from OpenAlex, Shouxi Xu has authored 31 papers receiving a total of 807 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Cellular and Molecular Neuroscience and 8 papers in Immunology. Recurrent topics in Shouxi Xu's work include Receptor Mechanisms and Signaling (10 papers), Mast cells and histamine (8 papers) and Neuropeptides and Animal Physiology (7 papers). Shouxi Xu is often cited by papers focused on Receptor Mechanisms and Signaling (10 papers), Mast cells and histamine (8 papers) and Neuropeptides and Animal Physiology (7 papers). Shouxi Xu collaborates with scholars based in United States, China and Switzerland. Shouxi Xu's co-authors include Najam A. Sharif, Julie Y. Crider, Gary W. Williams, John M. Yanni, Curtis R. Kelly, Ian Creese, David R. Sibley, Terry L. Davis, Daniel A. Gamache and Guo-Zhang Jin and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Life Sciences and British Journal of Ophthalmology.
In The Last Decade
Shouxi Xu
31 papers receiving 777 citations
Peers
Shouxi Xu
Naj Sharif United States
Charles E. Protzman United States
Louis DeSantis United States
Todd L. Anthony United States
Sina Bahmanyar United States
C. Nathaniel Roybal United States
R.A. Akhtar United States
Mohammadali Almasieh Canada
Yogita Dheer Australia
Shlomit Erlich Israel
Citations per year, relative to Shouxi Xu Shouxi Xu (= 1×)
peers
Naj Sharif
Countries citing papers authored by Shouxi Xu
Since
Specialization
Citations
This map shows the geographic impact of Shouxi Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shouxi Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shouxi Xu more than expected).
Fields of papers citing papers by Shouxi Xu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Shouxi Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shouxi Xu. The network helps show where Shouxi Xu may publish in the future.
Co-authorship network of co-authors of Shouxi Xu
This figure shows the co-authorship network connecting the top 25 collaborators of Shouxi Xu. A scholar is included among the top collaborators of Shouxi Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shouxi Xu. Shouxi Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sharif, Najam A., Linya Li, Shouxi Xu, et al.. (2014). Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule. Experimental Eye Research. 128. 170–180.
2.
Sharif, Najam A., Curtis R. Kelly, Linya Li, et al.. (2013). Trabecular Meshwork Bradykinin Receptors: mRNA Levels, Immunohistochemical Visualization, Signaling Processes Pharmacology, and Linkage to IOP Reduction. Journal of Ocular Pharmacology and Therapeutics. 30(1). 21–34.
3.
Sharif, Najam A., et al.. (2013). Human Non-Pigmented Ciliary Epithelium Bradykinin B2-Receptors: Receptor Localization, Pharmacological Characterization of Intracellular Ca2+Mobilization, and Prostaglandin Secretion. Current Eye Research. 39(4). 378–389.
4.
Sharif, Najam A., Marsha A. McLaughlin, Curtis R. Kelly, et al.. (2006). Preclinical Pharmacology of AL-12182, a New Ocular Hypotensive 11-Oxa Prostaglandin Analog. Journal of Ocular Pharmacology and Therapeutics. 22(5). 291–309.
5.
Sharif, Naj, Gary W. Williams, Julie Y. Crider, Shouxi Xu, & Terry L. Davis. (2004). Molecular Pharmacology of the DP/EP 2 Class Prostaglandin AL-6598 and Quantitative Autoradiographic Visualization of DP and EP 2 Receptor Sites in Human Eyes. Journal of Ocular Pharmacology and Therapeutics. 20(6). 489–508.
6.
Sharif, Najam A. & Shouxi Xu. (2004). Binding Affinities of Ocular Hypotensive β -Blockers Levobetaxolol, Levobunolol, and Timolol at Endogenous Guinea Pig β -Adrenoceptors. Journal of Ocular Pharmacology and Therapeutics. 20(2). 93–99.
7.
Sharif, Najam A., Curtis R. Kelly, Julie Y. Crider, Gary W. Williams, & Shouxi Xu. (2003). Ocular Hypotensive FP Prostaglandin (PG) Analogs: PG Receptor Subtype Binding Affinities and Selectivities, and Agonist Potencies at FP and Other PG Receptors in Cultured Cells. Journal of Ocular Pharmacology and Therapeutics. 19(6). 501–515.
8.
Sharif, Naj, Michelle Senchyna, & Shouxi Xu. (2002). Pharmacological and Molecular Biological (RT-PCR) Characterization of Functional TP Prostanoid Receptors in Immortalized Human Non-Pigmented Ciliary Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics. 18(2). 141–162.
9.
Sharif, Najam A., Shouxi Xu, Julie Y. Crider, Marκ McLaughlin, & Terry L. Davis. (2001). Levobetaxolol (Betaxon™) and Other β -Adrenergic Antagonists: Preclinical Pharmacology, IOP-Lowering Activity and Sites of Action in Human Eyes. Journal of Ocular Pharmacology and Therapeutics. 17(4). 305–317.
10.
Crider, Julie Y., Shouxi Xu, & Najam A. Sharif. (2001). Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets. Prostaglandins Leukotrienes and Essential Fatty Acids. 65(5-6). 253–258.
11.
Sharif, Najam A. & Shouxi Xu. (1999). Pharmacological Characterization of [ 3 H]-Ifenprodil Binding to Polyamine Binding Sites on Rabbit and Rat Retinal Homogenates: Role in Neuroprotection?. Journal of Ocular Pharmacology and Therapeutics. 15(3). 271–281.
12.
Sharif, Najam A. & Shouxi Xu. (1999). Human retina contains polyamine sensitive [3H]-ifenprodil binding sites: implications for neuroprotection?. British Journal of Ophthalmology. 83(2). 236–240.
13.
Crider, Julie Y., Brenda Walker Griffin, Shouxi Xu, & Najam A. Sharif. (1998). Use of a semi-automated, robotic radioimmunoassay to measure cAMP generated by activation of DP-, EP2-, and IP-prostaglandin receptors in human ocular and other cell types. Prostaglandins Leukotrienes and Essential Fatty Acids. 59(1). 77–82.
14.
Yanni, John M., Steven T. Miller, Daniel A. Gamache, et al.. (1997). Comparative Effects of Topical Ocular Anti-Allergy Drugs on Human Conjunctival Mast Cells. Annals of Allergy Asthma & Immunology. 79(6). 541–545.
15.
Sharif, Najam A., Shouxi Xu, & John M. Yanni. (1996). Olopatadine (AL-4943A): Ligand Binding and Functional Studies on a Novel, Long Acting H1-Selective Histamine Antagonist and Anti-Allergic Agent for Use in Allergic Conjunctivitis. Journal of Ocular Pharmacology and Therapeutics. 12(4). 401–407.
16.
Sharif, Najam A., et al.. (1996). Human Conjunctival Epithelial Cells Express Histamine-1 Receptors Coupled to Phosphoinositide Turnover and Intracellular Calcium Mobilization: Role in Ocular Allergic and Inflammatory Diseases. Experimental Eye Research. 63(2). 169–178.
17.
Sharif, Najam A. & Shouxi Xu. (1996). Pharmacological Characterization of Bradykinin Receptors Coupled to Phosphoinositide Turnover in SV40-Immortalized Human Trabecular Meshwork Cells. Experimental Eye Research. 63(6). 631–637.
18.
Creese, Ian, David R. Sibley, & Shouxi Xu. (1992). Expression of rat striatal D1 and D2 dopamine receptor mRNAs: Ontogenetic and pharmacological studies. Neurochemistry International. 20. 45–48.
19.
Xu, Shouxi, Frederick J. Monsma, David R. Sibley, & Ian Creese. (1992). Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sciences. 50(5). 383–396.
20.
Xu, Shouxi, et al.. (1989). [Experimental study of anti-tumor effect with conjugates of monoclonal antibodies and hematoporphyrin derivative].. PubMed. 24(6). 401–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Naj Sharif Breakdown of academic impact, for papers by Charles E. Protzman Breakdown of academic impact, for papers by Louis DeSantis Breakdown of academic impact, for papers by Todd L. Anthony Breakdown of academic impact, for papers by Sina Bahmanyar Breakdown of academic impact, for papers by C. Nathaniel Roybal Breakdown of academic impact, for papers by R.A. Akhtar Breakdown of academic impact, for papers by Mohammadali Almasieh Breakdown of academic impact, for papers by Yogita Dheer Breakdown of academic impact, for papers by Shlomit Erlich